Walleye Capital
ANTX icon

Walleye Capital’s AN2 Therapeutics ANTX Stock Holding History

Walleye Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
+72,139
New +$310K ﹤0.01% 3049
2024
Q3 		– Sell
-92,406
Closed -$199K – 5233
2024
Q2 		$199K Sell
92,406
-40,381
-30% -$96.1K ﹤0.01% 4306
2024
Q1 		$432K Buy
+132,787
New +$1.44M ﹤0.01% 3327

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Walleye Capital's ANTX Position: Q2 2026 in Review

Walleye Capital opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 72,139 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #3049 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ANTX as recently as Q2 2024.

Walleye Capital first reported a position in ANTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $432K in Q1 2024. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Walleye Capital held 72,139 shares of AN2 Therapeutics worth $349K as of Q2 2026.
  • AN2 Therapeutics was a new Walleye Capital position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3049 holding.
  • Walleye Capital first reported a position in AN2 Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Walleye Capital's AN2 Therapeutics position peaked at $432K in Q1 2024.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.